CELG Celgene Corporation

By Michael Dabaie

Bristol-Myers Squibb Co. (BMY) said Wednesday that the combined company from its proposed acquisition of Celgene Corp. (CELG) is expected to increase revenue and earnings per share every year through 2025.

Bristol-Myers on Wednesday issued an updated presentation on the transaction.

Bristol-Myers said to facilitate continued dialogue with the Federal Trade Commission, it would refile its premerger notification and report Wednesday, which will restart the 30-day time frame for the FTC's initial review of the transaction.

Bristol-Myers last month agreed to buy rival Celgene in a deal valued at about $74 billion, combining two leading sellers of cancer drugs.

The company said it plans to hold special meetings of stockholders on April 12 and the deal remains on track to close in the third quarter.

"Bristol-Myers Squibb is well positioned for 2025 and beyond with continued leadership across oncology and a diversified portfolio of assets. The combined company will have a broad, balanced and earlier life-cycle marketed portfolio with a significantly higher number of opportunities across multiple diseases to drive the growth of Bristol-Myers Squibb in the second half of the decade," the company said.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

February 20, 2019 09:52 ET (14:52 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.